Fluorescent biosensors for cancer cell imaging and diagnostics

Biosensors and Cancer

Volumn , Issue , 2012, Pages 101-124

  Morris, May C ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871063660     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Allen T. 2002. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2: 750-761.
2. Becker A, C Hessenius, K Licha, B Ebert, U Sukowski, W Semmler, B Wiedenmann and C Grötzinger. 2001. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 19: 327-31.
3. Carter SL, AC Eklund, IS Kohane, LN Harris and Z Szallasi. 2006. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-48.
4. Chen K, J Xie and X Chen. 2009. RGD-human serum albumin conjugates as efficient tumor targeting probes. Mol Imaging 8(2): 65-73.
5. Chudakov DM, MV Matz, S Lukyanov and KA Lukyanov. 2010. Fluorescent proteins and their applications in imaging living cells and tissues. Physiol Rev 90(3): 1103-63.
6. Dufort S, L Sancey, C Wenk, V Josserand and JL Coll. 2010. Optical small animal imaging in the drug discovery process. Biochim Biophys Acta 1798(12): 2266-73.
7. Frangioni JV. 2003. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 7: 626- 634.
8. Giuliano KA, DL Taylor and AS Waggoner. 2007. Reagents to measure and manipulate cell functions. Methods Mol Biol 356: 141-63.
9. Hanahan D and RA Weinberg. 2000. The hallmarks of cancer. Cell 100: 57-70.
10. Hoffmann RM. 2005. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 5: 796-806
11. Jiang T, ES Olson, QT Nguyen, M Roy, PA Jennings and RY Tsien. 2004. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 101: 17867-17872.
12. Jones CT, MT Catanese, LM Law, SR Khetani, AJ Syder, A Ploss, TS Oh, JW Schoggins, MR MacDonald, SN Bhatia and CM Rice. 2010. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol 28(2): 167-71.
13. Kaijzel EL, G van der Pluijm and CW Löwik. 2007. Whole-body optical imaging in animal models to assess cancer development and progression. Clin Cancer Res 13(12): 3490-7.
14. Kastan MB and J Bartek J. 2004. Cell Cycle Checkpoints and cancer. Nature 432: 316-323.
15. Keereweer S, JD Kerrebijn, PB van Driel, B Xie, EL Kaijzel, TJ Snoeks, I Que, M Hutteman, JR van der Vorst, JS Mieog, AL Vahrmeijer, CJ van de Velde, RJ Baatenburg de Jong and CW Löwik. 2010. Optical Image-guided Surgery-Where Do We Stand? Mol Imaging Biol [Epub ahead of print]
16. Kim YE, J Chen, JR Chan and R Langen. 2010a. Engineering a polarity-sensitive biosensor for time-lapse imaging of apoptotic processes and degeneration. Nat Methods 7: 67-73.
17. Kim K, JH Kim, H Park, YS Kim, K Park, H Nam, S Lee, JH Park, RW Park, IS Kim, K Choi, SY Kim, K Park and IC Kwon. 2010b. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 146(2): 219-27.
18. Kovar JL, W Volcheck, E Sevick-Muraca, MA Simpson and DM Olive. 2009. Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. Anal Biochem 384(2): 254-62.
19. Kroemer G and J Pouyssegur. 2008. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13(6): 472-82.
20. Kurzawa L and MC Morris. 2010. Cell Cycle Markers and Biosensors, Chem Bio Chem 11(8): 1037-47.
21. Kurzawa L, M Pellerano, JB Coppolani and MC Morris. 2011. Fluorescent peptide biosensor for probing the relative abundance of cyclin-dependent kinases in living cells. PloS One, 6(10): e26555.
22. Lapenna S and A Giordano. 2009. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8(7): 547-66.
23. Lang P, K Yeow, A Nichols and A Scheer. 2006. Cellular imaging in drug discovery. Nat Rev Drug Discovery 7: 591-607.
24. Lavis LD and RT Raines. 2008. Bright ideas for chemical biology. ACS Chem Biol 3: 142-55.
25. Law B and CH Tung. 2009. Proteolysis: a biological process adapted in drug delivery, therapy, and imaging. Bioconjug Chem 20(9): 1683-95.
26. Loving GS, M Sainlos and B Imperiali. 2010. Monitoring protein interactions and dynamics with solvatochromic fluorophores. Trends Biotechnol 28: 73-83.
27. Ludwig JA and J N Weinstein. 2005. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-56.
28. Malumbres M and M Barbacid. 2001. To Cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1, 222.
29. Malumbres M and M Barbacid. 2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3): 153-66.
30. Massoud TF and SS Gambhir. 2003. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17(5): 545-80.
31. Miyawaki A, J Llopis, R Heim, JM McCaffery, JA Adams, M Ikura and RY Tsien. 1997. Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin. Nature 388: 882-7.
32. Moore A, WZ Medarova, A Potthast and G Dai. 2004. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 64: 1821-1827.
33. Morris MC. 2010. Fluorescent Biosensors of Intracellular Targets: from Genetically-encoded Reporters to Modular Polypeptide Probes. Cell Biochem Biophys 56: 19-37.
34. Ohnishi S, SJ Lomnes, RG Laurence, A Gogbashian, G Mariani and JV Frangioni. 2005. Organic alternatives to quantum dots for intraoperative near-infrared fluorescent sentinel lymph node mapping. Molecular Imaging 4: 172-181.
35. Pierce MC, DJ Javier and R Richards-Kortum. 2008. Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int J Cancer 123: 1979-1990.
36. Reshetnyak YK, L Yao, S Zheng, S Kuznetsov, DM Engelman and OA Andreev. 2010. Measuring Tumor Aggressiveness and Targeting Metastatic Lesions with Fluorescent pHLIP. Mol Imaging Biol.
37. Sahai E. 2007. Illuminating the metastatic process. Nature Rev Cancer 7: 737-749.
38. Schrama D, R Reisfeld and J Becker. 2006. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discovery 5: 147-159.
39. Slakter JS, LA Yannuzzi, DR Guyer, JA Sorenson and DA Orlock. 1995. Indocyanine-green angiography. Curr Opin Ophthalmol 6(3): 25-32.
40. Tsien RY. 2005. Building and breeding molecules to spy on cells and tumors. FEBS Lett 579(4): 927-32.
41. Tung CH. 2004. Fluorescent peptide probes for in vivo diagnostic imaging. Biopolymers. 76(5): 391-403.
42. Urano Y, D Asanuma, Y Hama, Y Koyama, T Barrett, M Kamiya, T Nagano, T Watanabe, A Hasegawa, PL Choyke and H Kobayashi. 2009. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 15: 104-109.
43. Wang H, E Nakata and I Hamachi. 2009. Recent progress in strategies for the creation of protein-based fluorescent biosensors. Chem biochem 10: 2560-2577.
44. Weissleder R and M Pittet M. 2008. Imaging in the era of molecular oncology. Nature 452: 580-589.
45. Weissleder R, CH Tung, U Mahmood and A Bogdanov Jr. 1999. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17: 375-378.
46. Whitfield M, LK George, GD Grant and CM Perou. 2006. Common markers of proliferation. Nat Rev Cancer 6: 99-106.
47. Willmann JK, N van Bruggen, LM Dinkelborg and SS Gambhir. 2008. Molecular imaging in drug development. Nature Reviews Drug Discovery 7: 591-607.
48. Zhang J, RE Campbell, AY Ting and RY Tsien RY. 2002. Creating new fluorescent probes for cell biology. Nat Rev Mol Cell Biol 3(12): 906-18.